NEW YORK, March 23 – Vincent Kazmer said Friday he was resigning as chief financial officer of NetGenics to join Phase-1 Molecular Toxicology as CEO.
“Phase-1 is a good opportunity,” Kazmer said. His resignation is effective immediately and he will start work at Phase-1 Molecular Toxicology in April.
The company, which is based in Santa Fe, NM, uses gene expression technologies and bioinformatics to help improve lead optimization and diminish toxic effects early in a drug’s development.
Phase-1’s founder Spencer Farr will head the company’s R&D division.